We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

UBS UK Equity Income Class C - Income (GBP)

Sell:67.12p Buy:67.12p Change: 0.32p (0.47%)
Prices as at 7 November 2024
Sell:67.12p
Buy:67.12p
Change: 0.32p (0.47%)
You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Invest now
Prices as at 7 November 2024
Sell:67.12p
Buy:67.12p
Change: 0.32p (0.47%)
Prices as at 7 November 2024
You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Invest now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Our view on this Fund

This fund does not feature on the Wealth Shortlist of funds our analysts believe have the potential to outperform their peers over the long term. This is not a recommendation to sell; however, if you are thinking of adding to your investments, we believe the Wealth Shortlist is a good place to start. View funds on the Wealth Shortlist »

Our view on the sector

Equity income funds are popular with investors. Most aim to generate a rising income, and increase the value of your original investment, over the long term. The income can be paid out, or reinvested in the fund to boost long-term growth. Different fund managers take different approaches to income investing. Some focus on larger companies that are seen to be more stable and have paid regular dividends for many years. Others invest in higher-risk small and medium-sized companies. These might pay a lower income to start with, but have more growth potential. We think carefully chosen equity income funds can form the cornerstone of almost any portfolio.

Performance Analysis

Performance analysis for this fund is not available.

Investment Philosophy

Investment philosophy for this fund is not available.

Process and Portfolio Construction

Process and portfolio construction for this fund are not available.

question mark Manager Track Record Based on HL Quantitative Research

This information is currently unavailable.

Fund Track Record

07/11/19 to 07/11/20 07/11/20 to 07/11/21 07/11/21 to 07/11/22 07/11/22 to 07/11/23 07/11/23 to 07/11/24
Annual return -33.20% 52.60% 6.19% 4.72% 16.29%

Please remember past performance is not a guide to future returns. Where no data is shown, figures are not available. This information is provided to help you choose your own investments, remember they can fall as well as rise in value so you may not get back the original amount invested.

Information about the fund

Fund manager biography

manager photo
Manager Name: Steven Magill
Manager start date: 29 April 2013
Manager located in: tbc

Steve Magill is a Senior Portfolio Manager with a focus on UK Value Equity strategies. Steve joined UBS Global Asset Management in 1986, originally as an investment assistant. He took a career break between 1990 and 1993 to study, returning as a UK Equity Portfolio Manager. In 2000, Steve became a Pan-European pharmaceutical research analyst, taking on the role of Deputy Head of European Research in 2007. During this period Steve also co-ordinated the Global Healthcare team. He took on his current role in 2009. Steve is a Regular Member of the CFA Society of the UK and the CFA Institute.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Benchmark data provided subject to this disclaimer.
You can buy or sell holdings in this fund through a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Invest now